Cardiac radionuclide imaging to assess patients with heart failure

Seminars in Nuclear Medicine

Volumn 44, Issue 4, 2014, Pages 294-313

  Travin, Mark I ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; TRACER;

ACCURACY; AUTONOMIC INNERVATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE REMODELING; HUMAN; IMAGE ANALYSIS; ISCHEMIC CARDIOMYOPATHY; MYOCARDIAL PERFUSION IMAGING; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; QUANTITATIVE ANALYSIS; REVIEW; ANGIOGENESIS; ANIMAL; AUTONOMIC NERVOUS SYSTEM; COMPLICATION; HEART; INNERVATION; PATHOLOGY; PROCEDURES; SCINTISCANNING;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; HEART; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RADIONUCLIDE IMAGING;

EID: 84902591101     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2014.04.005     Document Type: Review

References (219)

1. V.I. Roger, A.S. Go, and D.M. Lloyd-Jones et al. Heart disease and stroke statistics - 2012 update: A report from the American Heart Association Circulation 125 2012 e2 e220
2. V.I. Roger, S.A. Weston, and M.M. Redfield et al. Trends in heart failure incidence and survival in a community-based population J Am Med Assoc 292 2004 344 350
3. D. Levy, S. Kenchaiah, and M.G. Larson et al. Long-term trends in the incidence of and survival with heart failure N Engl J Med 347 2002 1397 1402
4. W.J. Paulus, C. Tschöpe, and J.E. Sanderson et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J 28 2007 2539 2550
5. M.R. Zile, J.S. Gottdiener, and S.J. Hetzel et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and preserved ejection fraction Circulation 124 2011 2491 2501
6. F.M. Bengel Clinical cardiovascular molecular imaging J Nucl Med 50 2009 837 840
7. E. Braunwald Heart failure J Am Coll Cardiol Heart Fail 1 2013 1 20
8. J.N. Cohn, and R. Ferrari Sharpe N on behalf of an international forum on cardiac remodeling: Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling J Am Coll Cardiol 35 2000 569 582
9. S.A. Hunt, W.T. Abraham, and M.H. Chin et al. 2009 Focused update incorporated into the ACC/AHA 2005 guideline for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 119 2009 e391 e479
10. H.W. Strauss, B.L. Zaret, and P.J. Hurley et al. A scintigraphic method for measuring left ventricular ejection fraction in man without cardiac catheterization Am J Cardiol 28 1971 499 620
11. B.L. Zaret, H.W. Strauss, and P.J. Hurley et al. Left ventricular ejection fraction and regional myocardial performance in man without cardiac catheterization Circulation 42 suppl III 1970 120
12. B.L. Zaret, H.W. Strauss, and P.J. Hurley et al. A noninvasive scintigraphic method for detecting regional ventricular dysfunction in man N Engl J Med 284 1971 1165 1170
13. J. Alexander, N. Dainiak, and H.J. Berger et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography N Engl J Med 300 1979 278 283
14. R.G. Schwartz, W.B. McKenzie, and J. Alexander et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography Am J Med 82 1987 1109 1118
15. G.C. Fonarow, K.F. Adams, and W.T. Abraham et al. Risk stratification for in-hospital immortality n heart failure using classification and regression tree (CART) methodology analysis of 33,046 patients in the ADHERE registry J Card Fail 9 2003 S79 [abstract]
16. M. Gheorghiade, G. Sopko, and L. De Luca et al. Navigating the crossroads of coronary artery disease and heart failure Circulation 114 2006 1202 1213
17. A.L. Taylor, S. Ziesche, and C. Yancy et al. combination of isosorbide dinitrate and hydalazine in blacks with heart failure N Engl J Med 351 2004 2049 2057
18. G.M. Felker, L.K. Shaw, and C.M. O×Connor A standardized definition of ischemic cardiomyopathy for use of clinical research J Am Coll Cardiol 39 2002 210 218
19. J.E. Udelson, C.D. Shafer, and I. Carrió Radionuclide imaging in heart failure: Assessing etiology and outcomes and implications for management J Nucl Cardiol 9 2002 S40 S52
20. E.J. Eichhorn, E.J. Kosinski, and S.M. Lewis et al. Usefulness of dipyridamole-thallium-201 perfusion scanning for distinguishing ischemic from nonischemic cardiomyopathy Am J Cardiol 62 1988 945 951
21. A.S. Iskandrian, A.H. Hakki, and S. Kane Resting thallium-201 myocardial perfusion patterns in patients with severe left ventricular dysfunction: Differences between patients with primary cardiomyopathy, chronic coronary artery disease, or acute myocardial infarction Am Heart J 111 1986 76 767
22. V.F. Mody, R.C. Brunken, and L. Warner Stevenson et al. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography J Am Coll Cardiol 17 1991 373 383
23. S. Saltissi, B. Hockings, and D.N. Croft et al. Thallium-201 myocardial imaging in patients with dilated and ischemic cardiomyopathy Br Heart J 46 1981 290 295
24. S.G. Tauberg, J.E. Orie, and B.E. Bartlett et al. Usefulness of thallium-201 for distinction of ischemic from idiopathic dilated cardiomyopathy Am J Cardiol 71 1993 674 680
25. P.G. Danias, A.W. Ahlberg, and B.A. Clark III et al. Combined assessment of myocardial perfusion and left ventricular function with exercise technetium-99m sestamibi gated single-photon emission computed tomography can differentiate between ischemic and nonischemic dilated cardiomyopathy Am J Cardiol 82 1998 1253 1258
26. T.A. Holly, B.G. Abbott, and M. Al-Mallah et al. Single photon-emission computed tomography J Nucl Cardiol 17 2010 941 973
27. P. Soman, A. Lahiri, and J.H. Mieres et al. Etiology and pathophysiology of new-onset heart failure: Evaluation by myocardial perfusion imaging J Nucl Cardiol 16 2009 82 91
28. G.A. Beller Underestimation of coronary artery disease with SPECT perfusion imaging J Nucl Cardiol 15 2008 151 153
29. A.S. Iskandrian, J. Heo, and J. Lemlek et al. Identification of high-risk patients with left main and three-vessel coronary artery disease using stepwise discriminant analysis of clinical, exercise, and tomographic thallium data Am Heart J 125 1993 221 225
30. T.F. Christian, T.D. Miller, and K.R. Bailey et al. Noninvasive identification of severe coronary artery disease using exercise tomographic thallium-201 imaging Am J Cardiol 70 1992 14 20
31. M. Ragosta, A.H. Bishop, and L.C. Lipson et al. Comparison between angiography and fractional flow reserve versus single-photon emission computed tomographic myocardial perfusion imaging for determining lesion significance in patients with multivessel coronary disease Am J Cardiol 99 2007 896 902
32. D.S. Berman, X. Kang, and P.J. Slomka et al. Underestimation of extent of ischemia by gated SPECT myocardial perfusion imaging in patients with left main coronary artery disease J Nucl Cardiol 14 2007 521 528
33. A. Abidov, J.J. Bax, and S.W. Hayes et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT J Am Coll Cardiol 42 2003 1818 1825
34. R. Doukky, N. Frogge, and Y.A. Bayissa et al the prognostic value of transient ischemic dilatation with otherwise normal SPECT myocardial perfusion imaging: A cautionary note in patients with diabetes and coronary artery disease J Nucl Cardiol 20 2013 774 784
35. M.A. Mandour Ali, J.M. Bourque, and A.H. Allam et al the prevalence and predictive accuracy of quantitatively defined transient ischemic dilation of the left ventricle on otherwise normal SPECT myocardial perfusion imaging studies J Nucl Cardiol 18 2011 1036 1043
36. C. Valdiviezo, A.A. Motivala, and R. Hachamovitch et al the significance of transient dilation in the setting of otherwise normal SPECT radionuclide myocardial perfusion images J Nucl Cardiol 18 2011 220 229
37. R. Parkash, R.A. deKemp, and T.D. Ruddy et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease J Nucl Cardiol 11 2004 440 449
38. M.C. Ziadi, R.A. deKemp, and K. Williams et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease J Nucl Cardiol 19 2012 67 80
39. 13N-ammonia myocardial perfusion positron emission tomography J Am Coll Cardiol 54 2009 150 156
40. V.L. Murthy, M. Naya, and C.R. Foster et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve Circulation 123 2011 2215 2224
41. M.C. Ziadi, R.A. deKemp, and K.A. Williams et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia J Am Coll Cardiol 58 2011 740 748
42. H. Gewirtz Cardiac PET: A versatile, quantitative measurement tool for heart failure management J Am Coll Cardiol Imaging 4 2011 292 302
43. P.G. Camici, and F. Crea Coronary microvascular dysfunction N Engl J Med 356 2007 830 840
44. D. Neglia, O. Parodi, and M. Gallopin et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure: A quantitative assessment by positron emission tomography Circulation 92 1995 796 804
45. D. Neglia, C. Michelassi, and M.G. Trivieri et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction Circulation 105 2002 186 193
46. V. Dilsizian, R.O. Bonow, and S.E. Epstein et al. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy J Am Coll Cardiol 22 1993 796 804
47. V. Dilsizian, J.A. Panza, and R.O. Bonow Myocardial perfusion imaging in hypertrophic cardiomyopathy J Am Coll Cardiol Imaging 3 2010 1078 1080
48. R.O. Cannon, V. Dilsizian, and P.T. O×Gara et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy Circulation 85 1992 1039 1045
49. T. Mori, H. Yamabe, and Y. Yokota et al. Clinical significance of dipyridamole Tl-201 emission computed tomography perfusion abnormality for evaluating pathophysiological and pathological aspects in hypertrophic cardiomyopathy Jpn Circ J 52 1988 111 118
50. J. Shirani, and V. Dilsizian Nuclear cardiac imaging in hypertrophic cardiomyopathy J Nucl Cardiol 18 2011 123 134
51. J.E. Udelson, R.O. Bonow, and P.T. O×Gara et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy Circulation 79 1989 1052 1060
52. T.W. Von Dohlen, L.M. Prisant, and M.J. Frank Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy Am J Cardiol 64 1989 498 503
53. P. Camici, G. Chiriatti, and R. Lorenzoni et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography J Am Coll Cardiol 17 1991 879 886
54. P.G. Camici, F. Cecchi, and A. Montereggi et al. Dipyridamole induced subendocardial underperfusion in hypertrophic cardiomyopathy assessed by positron-emission tomography Coron Artery Dis 2 1991 837 841
55. L. Choudhury, P. Elliott, and O. Rimoldi et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment Basic Res Cardiol 94 1999 49 59
56. I. Olivotto, F. Cecchi, and P.G. Camici Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences Ital Heart J 5 2004 572 580
57. R. Lorenzoni, R. Gistri, and F. Cecchi et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction Am Heart J 136 1998 972 981
58. I. Olivotto, F. Cecchi, and R. Gistri et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy J Am Coll Cardiol 47 2006 1043 1048
59. P. Cecchi, I. Olivotto, and R. Gistri et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy N Engl J Med 349 2003 1027 1035
60. R.O. Bonow Identification of viable myocardium Circulation 94 1996 2674 2680
61. J.E. Udelson Steps forward in the assessment of myocardial viability in left ventricular dysfunction Circulation 97 1998 833 838
62. M.I. Travin, and S.R. Bergmann Assessment of myocardial viability Semin Nucl Med 35 2005 2 16
63. S. Rahimtoola Coronary bypass surgery for chronic angina - 1981: A perspective Circulation 65 1982 225 241
64. S.H. Rahimtoola The hibernating myocardium Am Heart J 117 1989 211 221
65. R.A. Kloner, R. Bolli, and E. Marban et al. Medical and cellular implications of stunning, hibernation, and preconditioning. An NHLBI workshop Circulation 97 1998 1848 1867
66. J.L.J. Vanoverschelde, W. Wijins, and C. Depre et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium Circulation 87 1993 1513 1523
67. E.J. Topol, J.L. Weiss, and J.A. Brinker et al. Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: Importance of coronary angioplasty J Am Coll Cardiol 6 1985 426 433
68. B.C. Berger, D.D. Watson, and L.R. Burwell et al. Redistribution of thallium at rest in patients with stable and unstable angina and the effect of coronary artery bypass surgery Circulation 60 1979 1114 1125
69. A.S. Iskandrian, A. Hakki, and S.A. Kane et al. Rest and redistribution thallium-201 myocardial scintigraphy to predict improvement in left ventricular function after coronary arterial bypass grafting Am J Cardiol 51 1983 1312 1316
70. 18F-fluorodeoxyglucose Circulation 83 1991 26 37
71. V. Dilsizian, T.P. Rocco, and N.M.T. Freedman et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging N Engl J Med 323 1990 141 146
72. R.S. Gibson, D.D. Watson, and G.J. Taylor et al. Prospective assessment of regional myocardial perfusion before and after coronary revascularization surgery by quantitative thallium-201 scintigraphy J Am Coll Cardiol 1 1983 804 815
73. J. Gutman, D.S. Berman, and M. Freeman et al. Time to completed redistribution of thallium-201 in exercise myocardial scintigraphy: Relationship to the degree of coronary artery stenosis Am Heart J 106 1983 989 995
74. H. Kiat, D.S. Berman, and J. Maddahi et al. Late reversibility of tomographic myocardial thallium-201 defects: An accurate marker of myocardial viability J Am Coll Cardiol 12 1988 1456 1463
75. P. Liu, M.C. Kiess, and R.D. Okada et al the persistent defect on exercise thallium imaging and its fate after myocardial revascularization: Does it represent scar or ischemia? Am Heart J 110 1985 996 1001
76. 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function Circulation 87 1993 1630 1641
77. J. Tillisch, R. Brunken, and R. Marshall et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography N Engl J Med 314 1986 884 888
78. P.R. Pagley, G.A. Beller, and D.D. Watson et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability Circulation 96 1997 793 800
79. A. Cuocolo, L. Pace, and B. Ricciardelli et al. Identification of viable myocardium in patients with chronic coronary artery disease: Comparison of thallium-201 scintigraphy with reinjection and technetium-99m methoxyisobutyl isonitrile J Nucl Med 33 1992 505 511
80. C. Marcassa, M. Galli, and A. Cuocolo et al. Rest-redistribution thallium-201 and rest technetium-99m-sestamibi SPECT in patients with stable coronary artery disease and ventricular dysfunction J Nucl Med 38 1997 419 424
81. P. Marzullo, G. Sambuceti, and O. Parodi The role of sestamibi scintigraphy in the radioisotopic assessment of myocardial viability J Nucl Med 33 1992 1925 1930
82. 99mTc-sestamibi Circulation 89 1994 2552 2561
83. 99mTc sestamibi in patients undergoing cardiac transplantation. A scintigraphic/pathologic study Circulation 94 1996 1010 1017
84. G.J. Kauffman, T.S. Boyne, and D.D. Watson et al. Comparison of rest thallium-201 imaging and rest technetium-99m sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction J Am Coll Cardiol 27 1996 1592 1597
85. G. Bisi, R. Sciagrà, and G.M. Santoro et al. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories J Am Coll Cardiol 24 1994 1282 1289
86. R. Sciagrà, G. Bisi, and G.M. Santoro et al. Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201 tomography in detecting viable hibernating myocardium and predicting postrevascularization recovery J Am Coll Cardiol 30 1997 384 391
87. H.J. Siebelink, P.K. Blanksma, and H.J.G.M. Crijns et al. No difference in cardiac event-free survival between positron emission tomography-guided single-photon emission computed tomography-guided patient management J Am Coll Cardiol 37 2001 81 88
88. K.C. Allman, L.J. Shaw, and R. Hachamovitch et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis J Am Coll Cardiol 39 2002 1151 1158
89. R. Rohatgi, S. Epstein, and J. Henriquez et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction Am J Cardiol 87 2001 1096 1099
90. R.S.B. Beanlands, T.D. Ruddy, and R.A. deKemp et al. Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function J Am Coll Cardiol 40 2002 1735 1743
91. R.S. Beanlands, G. Nichol, and E. Huszti et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2) J Am Coll Cardiol 50 2007 2002 2012
92. G. D×Egidio, G. Nichol, and K.A. Williams et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: A substudy of the PARR-2 trial JACC Cardiovasc Imaging 2 2009 1060 1068
93. A.F. Schinkel, J.J. Bax, and D. Poldermans et al. Hibernating myocardium: Diagnosis and patient outcomes Curr Probl Cardiol 32 2007 375 410
94. R.O. Bonow, G. Maurer, and K.L. Lee et al. Myocardial viability and survival in ischemic left ventricular dysfunction N Engl J Med 364 2011 1617 1625
95. Y. Inaba, J.A. Chen, and S.R. Bergmann Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis J Nucl Cardiol 17 2010 646 654
96. K.C. Allman Noninvasive assessment of myocardial viability: Current status and future directions J Nucl Cardiol 20 2013 618 637
97. C. Rischpler, S.G. Nekolla, and I. Dregely et al. Hybrid PET/MR imaging of the heart: Potential, initial experiences, and future prospects J Nucl Med 54 2013 402 415
98. L. Mielniczuk, and R. Beanlands Imaging-guided selection of patients with ischemic heart failure for high risk revascularization improves identification of those with the highest clinical benefit Circ Cardiovasc Imaging 5 2012 262 270
99. E. O×Meara, L.M. Mielniczuk, and G.A. Wells et al. Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: Study protocol for a randomized controlled trial Trials 14 2013 218 10.1186/1745-6215-14-218
100. A.J. Sinusas, J.D. Thomas, and G. Mills The future of molecular imaging J Am Coll Cardiol Imaging 4 2011 799 806
101. A. Abidov, P.J. Slomka, and H. Nishina et al. Left ventricular shape index assessed by gated stress myocardial perfusion SPECT: Initial description of a new variable J Nucl Cardiol 13 2006 652 659
102. E.H. Botvinick, M.A. Frais, and D.W. Shosa et al. An accurate means of detecting and characterizing abnormal patterns of ventricular activation by phase image analysis Am J Cardiol 50 1982 289 298
103. E. Botvinick, R. Dunn, and M. Frais et al the phase image: Its relationship to patterns of contraction and conduction Circulation 65 1982 551 560
104. E.H. Botvinick Scintigraphic blood pool and phase image analysis: The optimal tool for the evaluation of resynchronization therapy J Nucl Cardiol 10 2003 424 428
105. L. Fauchier, O. Marie, and D. Casset-Senon et al. Interventricular and intraventricular dyssynchrony in idiopathic dilated cardiomyopathy. A prognostic study with Fourier phase analysis of radionuclide angioscintigraphy J Am Coll Cardiol 40 2002 2022 2030
106. W.F. Kerwin, E.H. Botvinick, and J.W. O×Connell et al. Ventricular contraction abnormalities in dilated cardiomyopathy: Effect of biventricular pacing to correct interventricular dyssynchrony J Am Coll Cardiol 35 2000 1221 1227
107. J. Chen, E.V. Garcia, and J.J. Bax et al. SPECT myocardial perfusion imaging for the assessment of left ventricular mechanical dyssynchrony J Nucl Cardiol 18 2011 685 694
108. M. Trimble, E. Velazquez, and G. Adams et al. Repeatability and reproducibility of phase analysis of gated single-photon emission computed tomography myocardial perfusion imaging used to quantify cardiac dyssynchrony Nucl Med Commun 29 2008 374 381
109. M.M. Boogers, S.D. Van Kriekinge, and M.M. Henneman et al. Quantitative gated SPECT-derived phase analysis on gated myocardial perfusion SPECT detects left ventricular dyssynchrony and predicts response to cardiac resynchronization therapy J Nucl Med 50 2009 718 725
110. M. Friehling, J. Chen, and S. Saba et al. A prospective pilot study to evaluate the relationship between acute change in left ventricular synchrony after cardiac resynchronization therapy and patient outcome using a single-injection gated SPECT protocol Circ Cardiovasc Imaging 4 2011 532 539
111. M.M. Henneman, J. Chen, and P. Dibbets-Schneider et al. Can LV dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT? J Nucl Med 48 2007 1104 1111
112. M.J. Boogers, J. Chen, and R.J. van Bommel et al. Optimal left ventricular lead position assessed with phase analysis on gated myocardial perfusion SPECT Eur J Nucl Med Mol Imaging 38 2011 230 238
113. C. Ypenburg, M.J. Schalij, and G.B. Bleeker et al. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients Eur Heart J 28 2007 33 41
114. F. Ruschitzka, W.T. Abraham, and J.P. Singh et al. Cardiac- resynchronization therapy in heart failure with a narrow QRS complex N Engl J Med 369 2013 1395 1405
115. J.S. Hochman, and B.H. Bulkley Expansion of acute myocardial infarction: An experimental study Circulation 65 1982 1446 1450
116. M. Jessup, and S. Brozena Heart failure N Engl J Med 348 2003 2007 2018
117. C.M. Kramer, A.J. Sinusas, and D.E. Sosnovik et al. Multimodality imaging of myocardial injury and remodeling J Nucl Med 51 2010 107S 121S
118. A.R. Morrison, and A.J. Sinusas Advances in radionuclide molecular imaging in myocardial biology J Nucl Cardiol 17 2010 116 134
119. J.E. Rame Chronic heart failure: A reversible metabolic syndrome? Circulation 125 2012 2809 2811
120. H. Su, F.G. Spinale, and L.W. Dobrucki et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling Circulation 112 2005 3157 3167
121. Z.H. Sahul, R. Mukherjee, and J. Song et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling. Relationship to myocardial dysfunction Circ Cardiovasc Imaging 4 2011 381 391
122. I. Kehat, and J.D. Molkentin Molecular pathways underlying cardiac remodeling during pathophysiological stimulation Circulation 122 2010 2727 2735
123. T. Higuchi, F.M. Bengel, and S. Seidl et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography Cardiovasc Res 178 2008 395 403
124. M.R. Makowski, U. Ebersberger, and S. Nekolla et al. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction Eur Heart J 29 2008 2201
125. J.W. Verjans, S.L. Wolters, and M. Lax et al. Imaging αvβ3/β5 integrin upregulation in patients after myocardial infarction Circulation 116 II 2007 740 [abstract]
126. M.S. Cocker, G. Dwivedi, and B. Marvin et al. Integrin imaging for the detection of diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy: Direct comparison between single-photon emission computer tomography and cardiovascular magnetic resonance The SCAR Study Circulation 126 2012 A19661 [abstract]
127. A. Altumairi, R. Rossin, and M. Shokeen et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis Proc Natl Acad Sci U S A 106 2009 685 690
128. S.W. Van den Borne, S. Isobe, and J.W. Verjans et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction J Am Coll Cardiol 52 2008 2017 2028
129. A. Chokshi, K. Drosatos, and F.H. Cheema et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure Circulation 125 2012 2844 2853
130. B.A. McArdle, E. Leung, and H. Ohira et al the role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis J Nucl Cardiol 20 2013 297 306
131. O. Aras, S.A. Messina, and J. Shirani et al the role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure Curr Cardiol Rep 9 2007 150 158
132. J. Shirani, M.L. Loredo, and W.C. Eckelman et al. Imaging the renin-angiotensin-aldosterone system in the heart Curr Heart Fail Rep 2 2005 78 86
133. K.T. Weber Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation Circulation 96 1997 4065 4082
134. R. Re The clinical implication of tissue rennin angiotensin systems Curr Opin Cardiol 16 2001 317 327
135. K. Harada, T. Sugaya, and K. Murakami et al. Angiotensin II type IA receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction Circulation 100 1999 2093 2099
136. A.H.J. Danser, C.A.M. van Kesteren, and W.A. Bax et al. Prorenin, renin, angiotensin and angiotensin converting enzyme in normal and failing hearts: Evidence for rennin binding Circulation 96 1997 220 226
137. 18F] fluorobenzoyl lisinopril: A radioligand for angiotensin converting enzyme (ACE) imaging with positron emission tomography J Labelled Compounds Radiopharm 44 suppl 2001 S268 S270
138. V. Dilsizian, W.C. Eckelman, and M.L. Loredo et al. Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique J Nucl Med 48 2007 182 187
139. T. Higuchi, K. Fukushima, and J. Xia et al. Radionuclide imaging of angiotensin II type 1 receptor upregulation after myocardial ischemia-reperfusion injury J Nucl Med 51 2010 1956 1961
140. K. Fukushima, P.E. Bravo, and T. Higuchi et al. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors J Am Coll Cardiol 60 2012 2527 2534
141. J.W.H. Verjans, D. Lovhaug, and N. Narula et al. Noninvasive imaging of angiotensin receptors after myocardial infarction J Am Coll Cardiol Imaging 1 2008 354 362
142. V. Dilsizian, T.K. Zynda, and A. Petrov et al. Molecular imaging of human ACE-1 expression in transgenic rats J Am Coll Cardiol 5 2012 409 418
143. 123I-mIBG imaging Semin Nucl Med 41 2011 374 387
144. F. Triposkiadis, G. Karayannis, and G. Giamouzis et al the sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications J Am Coll Cardiol 54 2009 1747 1762
145. A. Flotats, and I. Carrió Cardiac neurotransmission SPECT imaging J Nucl Cardiol 11 2004 587 602
146. M.I. Travin Cardiac autonomic imaging with SPECT tracers J Nucl Cardiol 20 2013 128 143
147. R.L. Verrier, and C. Antzelevich Autonomic aspects of arrhythmogenesis: The enduring and the new Curr Opin Cardiol 19 2004 2 11
148. D.M. Raffel, and D.M. Wieland Development of mIBG as a cardiac innervation imaging agent J Am Coll Cardiol Imaging 3 2010 111 116
149. J.C. Sisson, J.J. Lynch, and J. Johnson et al. Scintigraphic detection of regional disruption of adrenergic neurons in the heart Am Heart J 116 1988 67 76
150. M.A. Rabinovitch, C.P. Rose, and A.J. Schwab et al. A method of dynamic analysis of iodine-123-meta-iodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure J Nucl Med 34 1993 589 600
151. N. Hattori, and M. Schwaiger et al. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically? Eur J Nucl Med 27 2000 1 6
152. S. Vallabhajosula, and A. Nikolopoulou Radioiodinated metaiodobenzylguanidine (MIBG): Radiochemistry, biology, and pharmacology Semin Nucl Med 41 2011 324 333
153. 123I-MIBG scintigraphy in chronic heart failure Eur J Nucl Med Mol Imaging 36 2009 555 559
154. I. Carrió, M.R. Cowie, and J. Yamazaki et al. Cardiac sympathetic imaging with mIBG in heart failure J Am Coll Cardiol Imaging 3 2010 91 100
155. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials J Nucl Cardiol 16 2009 113 121
156. 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology Eur J Nucl Med Mol Imaging 37 2010 1802 1812
157. K.K. Solanki, J. Bomanji, and J. Moyes et al. A pharmacological guide to medicine which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG) Nucl Med Commun 13 1992 513 521
158. A.R. Wafelman, C.A. Hoefnagel, and R.A. Maes et al. Radio-iodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry Eur J Nucl Med 21 1994 545 559
159. Y. Inoue, A. Suzuki, and I. Shirouzu et al. Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake J Nucl Cardiol 10 2003 623 632
160. 123I-MIBG heart/mediastinum ratios: A phantom study Eur J Nucl Med Mol Imaging 32 2005 1100 1107
161. J. Chen, E.V. Garcia, and J.R. Galt et al. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging J Nucl Cardiol 13 2006 251 260
162. K. Okuda, K. Nakajima, and T. Hosoya et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 MIBG imaging J Nucl Cardiol 18 2011 82 89
163. G.P. Chen, R. Tabibiazar, and K.R. Branch et al. Cardiac receptor physiology and imaging: An update J Nucl Cardiol 12 2005 714 730
164. T. Morozumi, H. Kusuoka, and K. Fukuchi et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects J Nucl Med 38 1997 49 52
165. G.A. Somsen, H.J. Verberne, and E. Fleury et al. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: Implications for clinical studies J Nucl Cardiol 11 2004 126 133
166. 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: A prospective study Heart 86 2001 656 660
167. 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure Eur J Nucl Med Mol Imaging 39 2012 1599 1608
168. J.D. Minardo, M.M. Tuli, and B.H. Mock et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application Circulation 78 1988 1008 1019
169. M.V. Simões, P. Barthel, and I. Matsunari et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction Eur Heart J 25 2004 551 557
170. T. Wichter, P. Matheja, and L. Eckardt et al. Cardiac autonomic dysfunction in Brugada syndrome Circulation 105 2002 702 706
171. H. Lerch, P. Bartenstein, and T. Wichter et al. Sympathetic innervation of the left ventricle is impaired in arrhythmogenic right ventricular disease Eur J Nucl Med 20 1993 207 212
172. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study Circ Cardiovasc Imaging 1 2008 131 140
173. J. Schofer, R. Spielmann, and A. Schuchert et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy J Am Coll Cardiol 12 1988 1252 1258
174. P. Merlet, H. Valette, and J. Dubois-Randé et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure J Nucl Med 33 1992 471 477
175. T. Klein, V. Dilsizian, and Q. Cao et al the potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy Curr Cardiol Rep 15 5 2013 359 10.1007/s11886-013-0359-1
176. T. Nakata, K. Miyamoto, and A. Doi et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts J Nucl Cardiol 5 1998 579 590
177. H. Kioka, T. Yamada, and T. Mine et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging Heart 93 2007 1213 1218
178. 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review Eur Heart J 29 2008 1147 1159
179. D. Agostini, H.J. Verberne, and W. Burchert et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: Insights from a retrospective European multicenter study Eur J Nucl Med Mol Imaging 35 2008 535 546
180. A.F. Jacobson, R. Senior, and M.D. Cerqueira et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study J Am Coll Cardiol 55 2010 2212 2221
181. T. Nakata, K. Nakajima, and S. Yamashina et al. A pooled analysis of multicenter cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure J Am Coll Cardiol Imaging 6 2013 772 784
182. E.S. Ketchum, A.F. Jacobson, and J.H. Caldwell et al. Selective improvement in Seattle heart failure model risk stratification using iodine-123 meta-iodobenzylguanidine imaging J Nucl Cardiol 19 2012 1007 1016
183. W.C. Levy, D. Mozaffarian, and D.T. Linker et al the Seattle Heart Failure Model. Prediction of survival in heart failure Circulation 113 2006 1424 1433
184. L.J. Shaw, J.K. Min, and R. Hachamovitch et al. Cardiovascular imaging research at the crossroads J Am Coll Cardiol Imaging 3 2010 316 324
185. G. Treglia, I. Stefanelli, and B.A. Giordano Clinical usefulness of myocardial innervation imaging using Iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: An overview Eur Rev Med Pharmacol Sci 17 2013 56 58
186. M.C. Gerson, L.L. Craft, and N. McGuire et al. Carvedilol improves left ventricular function in heart failure with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine J Nucl Cardiol 9 2002 608 615
187. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy J Nucl Med 40 1999 217 223
188. S. Kasama, T. Toyama, and T. Hatori et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy on the treatment containing carvedilol Eur Heart J 28 2007 989 995
189. A. Cohen-Solal, F. Rouzet, and A. Berdeaux et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure J Nucl Med 46 2005 1796 1803
190. J.Y. Choi, K.H. Lee, and K.P. Hong et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity J Nucl Cardiol 8 2001 4 9
191. M. Suwa, Y. Otake, and A. Moriguchi et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy Am Heart J 133 1997 353 358 [erratum in Am Heart J 1997; 134:1141]
192. 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments - Comparison with neurohumoral factors Circ J 66 2002 537 543
193. S.G. Drakos, T. Athanasoulis, and K.G. Malliaras et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading J Am Coll Cardiol Imaging 3 2010 64 70
194. R.S. George, E.J. Birks, and A. Cheetham et al the effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy Eur J Heart Fail 15 2013 1035 1043
195. G.F. Tomaselli, and D.P. Zipes What causes sudden death in heart failure? Circ Res 95 2004 754 763
196. M. Jessup, W.T. Abraham, and D.E. Casey et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 53 2009 1343 1382
197. J.D. Fisher, and H.E. Ector Relative and absolute benefits: Main results should be reported in absolute terms. Pacing and clinical electrophysiology Pacing Clin Electrophysiol 30 2007 935 937
198. R.J. Myerburg Implantable cardioverter-defibrillators after myocardial infarction N Engl J Med 359 2008 2245 2253
199. D.S. Lee, A.D. Krahn, and J.S. Healey et al. Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database J Am Coll Cardiol 55 2010 774 782
200. A.I. McGhie, J.R. Corbett, and M.S. Akers et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction Am J Cardiol 67 1991 236 242
201. M.S. Stanton, M.M. Tuli, and N.L. Radtke et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG J Am Coll Cardiol 14 1989 1519 1526
202. M.C. Gerson, M. Abdallah, and J.N. Muth et al. Will imaging assist in the selection of patients with heart failure for an ICD? J Am Coll Cardiol Imaging 3 2010 101 110
203. R. Arora, K.J. Ferrick, and T. Nakata et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator J Nucl Cardiol 10 2003 121 131
204. D. Nagahara, T. Nakata, and A. Hashimoto et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function J Nucl Med 49 2008 225 233
205. 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction J Nucl Med 49 2008 907 914
206. S. Tamaki, T. Yamada, and Y. Okuyama et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion J Am Coll Cardiol 53 2009 426 435
207. M.J. Boogers, C.J. Borleffs, and M.M. Henneman et al. Cardiac sympathetic denervation assessed with 123-Iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients J Am Coll Cardiol 55 2010 2769 2777
208. P. Perrone-Filardi, S. Paolillo, and S. Dellegrottaglie et al. Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: A clinical appraisal Heart 97 2011 1828 1833
209. D.V. Exner, G.J. Klein, and E.N. Prystowsky Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?) Circulation 104 2001 1564 1570
210. A.M. Shah, M. Bourgoun, and J. Narula et al. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure J Am Coll Cardiol Imaging 5 2012 1139 1146
211. J.T. Thackeray, and F.M. Bengel Assessment of cardiac autonomic neuronal function using PET imaging J Nucl Cardiol 20 2013 150 165
212. 11C-mHED and PET: From man to mouse? J Nucl Med 51 2010 1269 1276
213. 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models Circ Cardiovasc Imaging 4 2011 435 443
214. 11C-Hydroxyephedrine retention in hibernating myocardium: Chronic inhomogeneity of sympathetic innervation in the absence of infarction J Nucl Med 46 2005 1368 1374
215. J.A. Fallavollita, and J.M. Canty Dysinnervated but viable myocardium in ischemic heart disease J Nucl Cardiol 17 2010 1107 1115
216. J.A. Fallavollita, B.M. Heavey, and A.J. Luisi Jr. et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy J Am Coll Cardiol 63 2014 141 149
217. 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy J Nucl Med 50 2009 220 225
218. 11C]CGP12388 Eur J Nucl Med Mol Imaging 32 2005 443 447
219. J.H. Caldwell, J.M. Link, and W.C. Levy et al. Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure J Nucl Med 49 2008 234 241